The Safety Analysis and Reasonable Medication Suggestion of Fleroxacin

Chinese Journal of Pharmacovigilance ›› 2011, Vol. 8 ›› Issue (9): 531-533.

Previous Articles Next Articles

The Safety Analysis and Reasonable Medication Suggestion of Fleroxacin

ZHANG Li-ming¹, DONG Duo², DING Qing-ming³, MA Jun-li¹, DU Xiao-xi^{2, *}

1 Beijing center for ADR monitoring, Beijing 100024,China;
2 National center for ADR monitoring, Beijing 100045, China;
3 China-Japan friendship hospital, Beijing 100029, China

Received:2010-08-25 Online:2011-09-10 Published:2015-07-30

Abstract

Abstract: Objective To understand the Fleroxacin safety and direct reasonable medication through analyzing Fleroxacin ADRs in first half year in 2006. Methods To retrieve ADRs in first half year in 2006 and analyze unreasonable medication. Results There are 1 661 ADRs caused by Fleroxacin and unreasonable medication exists. Conclusion There are unreasonable medications when use Fleroxacin clinically and reasonable use may reduce risk and enhance safety.

Key words: Fleroxacin, safety, reasonable medication

CLC Number:

R978

ZHANG Li-ming, DONG Duo, DING Qing-ming, MA Jun-li, DU Xiao-xi. The Safety Analysis and Reasonable Medication Suggestion of Fleroxacin[J]. Chinese Journal of Pharmacovigilance, 2011, 8(9): 531-533.

[1]	JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui. Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
[2]	MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
[3]	BAI Zhaofang, ZHAN Xiaoyan, YAO Qing, CHEN Simin, ZHAO Xu, XIAO Xiaohe. Theoretical innovation and technological breakthroughs in the safety evaluation of traditional Chinese medicine: disease-syndrome-based toxicology [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 6-14.
[4]	FANG Zhie, LI Chengxian, BAI Zhaofang, ZHAO Xu, WANG Jiabo, XIAO Xiaohe. Investigation of objectivity in the relationship between aristolochic acid and hepatocellular carcinoma [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 20-24.
[5]	XIONG Weiyi, REN Jingtian. Considerations for revision of safety information in package inserts of anti-cancer drugs in post-market phase [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 94-97.
[6]	LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
[7]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[8]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[9]	SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986.
[10]	YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin. Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
[11]	LIU Qian, HU Jing, LI Bo, YANG Xiaojing. Jinghuaweikang capsules combined with quadruple therapy in the treatment of Helicobacter pylori associated gastritis: a systematic evaluation and meta-analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1039-1045.
[12]	YU Hongli, YU Dongmei, XIAO Aili, ZHU Lan, SONG Haibo. Risks of safety Qingkailing oral preparation [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1046-1048.
[13]	LI Jing, XU Ye, LIU Ranjia, PAN Chen, CUI Xiangli. Adverse reactions in patients with COVID-19 after using tocilizumab [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1049-1053.
[14]	LI Yamei, SHUI Rong. Research progress in tofacitinib for juvenile idiopathic arthritis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 956-960.
[15]	WANG Rong, LIU Ziqun, WANG Nana, TAN Xiong, ZHANG Yixin, YANG Kuan, QIN Bei. Acute toxicity of proline Danshensu borneol ester in mice [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 754-757.

The Safety Analysis and Reasonable Medication Suggestion of Fleroxacin

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics